CGS-20625

CGS-20625

Clinical data
Routes of administration	By mouth
ATC code	none
Pharmacokinetic data
Bioavailability	41%
Identifiers
IUPAC name 5,6,7,8,9,10-hexahydro-2-(4-methoxyphenyl)-cyclohepta[b]pyrazolo[3,4-d]pyridin-3(2H)-one
CAS Number	111205-55-1  Y
PubChem CID	163844
ChemSpider	143700  N
UNII	K9Q4R9S81O
CompTox Dashboard (EPA)	DTXSID30912046
Chemical and physical data
Formula	C18H19N3O2
Molar mass	309.369 g·mol−1
3D model (JSmol)	Interactive image
SMILES COC1=CC=C(C=C1)N2C(=O)C3=CN=C4CCCCCC4=C3N2
InChI InChI=1S/C18H19N3O2/c1-23-13-9-7-12(8-10-13)21-18(22)15-11-19-16-6-4-2-3-5-14(16)17(15)20-21/h7-11,20H,2-6H2,1H3 N Key:UBLXQFIFWUEVGJ-UHFFFAOYSA-N N
NY  (what is this?)    (verify)

CGS-20625 is an anxiolytic drug used in scientific research. It has similar effects to benzodiazepine drugs, ^[1] but is structurally distinct and so is classed as a nonbenzodiazepine anxiolytic. ^{[2] [3]} It produces anxiolytic and anticonvulsant effects, but with no sedative effects even at high doses, and no significant muscle relaxant effects. ^[4] It is orally active in humans, but with relatively low bioavailability. ^[5]

CGS-20625 is a positive allosteric modulator at several GABA_A receptors types. Due to its alicyclic moiety potency at γ1 subunit, containing receptor types is more pronounced for CGS-20625 compared to benzodiazepines. ^{[1] [ further explanation needed ]} γ1 subunits are expressed at higher levels in the central amygdala. ^[6]

References

1. Khom S, Baburin I, Timin EN, Hohaus A, Sieghart W, Hering S (Feb 2006). "Pharmacological properties of GABAA receptors containing gamma1 subunits". Mol. Pharmacol. 69 (2): 640–9. doi:10.1124/mol.105.017236. PMID   16272224. S2CID   15082432.
2. Bennett DA (1987). "Pharmacology of the pyrazolo-type compounds: agonist, antagonist and inverse agonist actions". Physiol. Behav. 41 (3): 241–5. doi:10.1016/0031-9384(87)90360-X. PMID   2893398. S2CID   45892825.
3. Brunner LA, Luders RC (Aug 1991). "Determination of a potential anxiolytic drug (CGS 20625) in human plasma by high-performance liquid chromatography". J. Chromatogr. 568 (2): 487–93. doi:10.1016/0378-4347(91)80188-I. PMID   1686029.
4. Williams M, Bennett DA, Loo PS, et al. (Jan 1989). "CGS 20625, a novel pyrazolopyridine anxiolytic". J Pharmacol Exp Ther. 248 (1): 89–96. PMID   2563294.
5. Hirschberg Y, Oberle RL, Ortiz M, Lau H, Markowska M (Feb 1995). "Oral absorption of CGS-20625, an insoluble drug, in dogs and man". J Pharmacokinet Biopharm. 23 (1): 11–23. doi:10.1007/BF02353783. PMID   8576841. S2CID   22126140.
6. Esmaeili A, Lynch JW, Sah P (January 2009). "GABAA receptors containing gamma1 subunits contribute to inhibitory transmission in the central amygdala". J. Neurophysiol. 101 (1): 341–9. doi:10.1152/jn.90991.2008. PMID   19004994. S2CID   1590604.